CAI
CATX icon

Capital Advisors Inc’s Perspective Therapeutics CATX Stock Holding History

Capital Advisors Inc’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000
Closed -$11.9K – 311
2024
Q1 		$11.9K Hold
1,000
– – ﹤0.01% 303
2023
Q4 		$4.02K Hold
1,000
– – ﹤0.01% 286
2023
Q3 		$2.74K Hold
1,000
– – ﹤0.01% 261
2023
Q2 		$6.68K Hold
1,000
– – ﹤0.01% 271
2023
Q1 		$6.38K Hold
1,000
– – ﹤0.01% 254
2022
Q4 		$2.47K Hold
1,000
– – ﹤0.01% 251
2022
Q3 		$4K Hold
1,000
– – ﹤0.01% 239
2022
Q2 		$3K Hold
1,000
– – ﹤0.01% 243
2022
Q1 		$4K Hold
1,000
– – ﹤0.01% 252
2021
Q4 		$4K Hold
1,000
– – ﹤0.01% 247
2021
Q3 		$6K Hold
1,000
– – ﹤0.01% 230
2021
Q2 		$8K Hold
1,000
– – ﹤0.01% 236
2021
Q1 		$11K Hold
1,000
– – ﹤0.01% 232
2020
Q4 		$5K Hold
1,000
– – ﹤0.01% 212
2020
Q3 		$6K Hold
1,000
– – ﹤0.01% 199
2020
Q2 		$7K Buy
+1,000
New +$6.43K ﹤0.01% 188

Other funds holding CATX

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Advisors Inc's CATX Position: Q2 2024 in Review

Capital Advisors Inc sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 1,000 shares — an estimated $11.9K sold.

Capital Advisors Inc first reported a position in CATX in Q2 2020 and held it in 16 quarters. The position peaked at $11.9K in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

  • Capital Advisors Inc reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Capital Advisors Inc sold 1,000 Perspective Therapeutics shares in Q2 2024, an estimated $11.9K.
  • Capital Advisors Inc first reported a position in Perspective Therapeutics in Q2 2020 and held it in 16 quarters.
  • Capital Advisors Inc's Perspective Therapeutics position peaked at $11.9K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Capital Advisors Inc's 13F filing for Q2 2024, filed 31 Jul 2024.